Comparing radical prostatectomy and brachytherapy for localized prostate cancer

ONCOLOGY

Volumn 18, Issue 10, 2004, Pages 1289-1302

  Quaranta, Brian P ^a   Marks, Lawrence B ^a   Anscher, Mitchell S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

BRACHYTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; HUMAN; MALE; METHODOLOGY; PROSTATE TUMOR; PROSTATECTOMY; REVIEW; RISK FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

BRACHYTHERAPY; CLINICAL TRIALS; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 16644386892     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. D'Amico A, Whittington R, Malkowicz S, et al: Biochemical outcome after radical prostatectomy, external beam radiaiton therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998.
2. Sharkey J, Cantor A, Sole Z, et al: Brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer. Curr Urol Rep 3:250-257, 2002.
3. Walsh P: Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: A structured debate. J Urol 163:1802-1807, 2000.
4. Catalona WJ, Ramos CG, Carvalhal GF: Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin 49:282-296, 1999.
5. Walsh PC: Is Interstitial Radiotherapy Effective in Curing Prostate Cancer? Available at the James Buchanan Brady Urological Institute at Johns Hopkins Medical Institutions website, http://urology.jhu.edu. Accessed June 9, 2004.
6. Mixing Apples and Oranges: Using Two Standards to Determine Cure with Surgery and Radiation Therapy. Available at the James Buchanan Brady Urological Institute at Johns Hopkins Medical Institutions website, http://urology.jhu.edu. Prostate Cancer Update, Winter 2003. Accessed June 9, 2004.
7. Gretzer MB, Trock BJ, Han M, et al: A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J Urol 168(4 pt 1):1419-1422, 2002.
8. Polascik T, Pound C, DeWeese T, et al: Comparison of radical prostatectomy and idodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: A 7-year biochemical (PSA) progression analysis. Urology 51:884-889, 1998.
9. Amling CL, Blute ML, Bergstralh EJ, et al: Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued risk of biochemical failure after 5 years. J Urol 164:101-105, 2000.
10. Vicini FA, Kestin LL, Martinez AA: The importance of adequate follow-up in defining treatment success after external-beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 45:553-561, 1999.
11. Zelefsky M, Hollister T, Raben A, et al: Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 47:1261-1266, 2000.
12. Lederman G, Cavanaugh W, Albert P, et al: Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy. Int J Radiat Oncol Biol Phys 49:1297-1303, 2001.
13. Kollmeier M, Stock R, Stone N: Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57:645-653, 2003.
14. Ragde H, Korb L, Elgamal A, et al: Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 89:135-141, 2000.
15. Grimm P, Blasko J, Sylvester J, et al: 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51:31-40, 2001.
16. Sylvester JE, Blasko JC, Grimm PD, et al: Ten-year biochemical relapse-free survival functions following brachytherapy with external beam radiotherapy for patients with localized prostate cancer: The Seattle experience. Int J Radiat Oncol Biol Phys 54(2 suppl):38, 2002.
17. Stokes SH: Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiat Oncol Biol Phys 47:129-136, 2000.
18. Kwok Y, DiBiase S, Amin P, et al: Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy. Int J Radiat Oncol Biol Phys 53:588-594, 2002.
19. Critz F, Williams W, Levinson A, et al: Simultaneous irradiation for prostate cancer: Intermediate results with modern techniques. J Urol 164(3 pt 1):738-741, 2000.
20. Blasko J, Grimm P, Sylvester J, et al: Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 46:839-850, 2000.
21. Brachman D, Thomas T, Hilbe J, et al: Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: Results from a single practice. Int J Radiat Oncol Biol Phys 48:111-117, 2000.
22. Dattoli M, Wallner K, True L, et al: Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: Influence of prostatic acid phosphatase. Cancer 97:979-983, 2003.
23. Merrick GS, Butler WM, Galbreath RW, et al: Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys 51:41-48, 2001.
24. Merrick GS, Butler WM, Lief JH, et al: Biochemical outcome for hormone-naive patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation. Cancer J Sci Am 8:322-327, 2002.
25. Singh A, Zelefsky MJ, Raben A, et al: Combined 3-dimensional conformal radiotherapy and transperineal Pd-103 permanent implantation for patients with intermediate and unfavorable risk prostate cancer. Int J Cancer 90:275-280, 2000.
26. Blank L, Gonzalez D, De Reijke T, et al: Brachytherapy with transperineal (125) Iodine seeds for localized prostate cancer. Radiother Oncol 57:307-313, 2000.
27. Koutrouvelis P, Gillenwater J, Lailas N, et al: High and intermediate risk prostate cancer treated with three-dimensional computed tomography-guided brachytherapy: 2-8 year follow-up. Radiother Oncol 67:303-308, 2003.
28. Iversen P, Rasmussen F, Holm HH: Long-term results of ultrasonically guided implantation of 125-I seeds combined with external irradiation in localized prostatic cancer. Scand J Urol Nephrol 138(suppl):109-115, 1991.
29. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998.
30. Vicini FA, Martinez A, Hanks G, et al: An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer 95:2126-2135, 2002.
31. Han M, Partin AW, Pound CR, et al: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. Urol Clin North Am 28:555-565, 2001.
32. Kupelian PA, Elshaikh M, Reddy C, et al: Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: A large single-institution experience with radical prostatectomy and external beam radiotherapy. J Clin Oncol 20:3376-3385, 2002.
33. Paulson DF, Vieweg JWG: Radical perineal prostatectomy: A model for evaluating local response of prostate therapy. Crit Rev Oncol Hematol 43:135-139, 2002.
34. Blute ML, Bergstraith EJ, Iocca A, et al: Use of gleason score, prostate-specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 165:119-125, 2001.
35. Stein A, DeKernion JB, Smith RB, et al: Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol 147:942-946, 1992.
36. Barry MJ, Albertsen PC, Bagshaw MA, et al: Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management. Cancer 91:2302-2314, 2001.
37. Ramos C, Carvalhal G, Smith D, et al: Retrospective comparison of radical retropubic prostatectomy and 125 Iodine brachytherapy for localized prostate cancer. J Urol 161:1212-1215, 1999.
38. Ragde H, Elgamal A, Snow P, et al: Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 83:989-1001, 1998.
39. Han M, Partin AW, Piantadosi S, et al: Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 166:416-419, 2001.
40. Amling CL, Bergstralh EJ, Blute ML, et al: Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? J Urol 165:1146-1151, 2001.
41. Kuban DA, Thames HD, Levy LB: Radiation for prostate cancer: Use of biochemical failure as an endpoint following radiotherapy. World J Urol 21:253-264, 2003.
42. Kattan MW, Fearn PA, Leibel SA, et al: The definition of biochemical failure in patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 48:1469-1474, 2000.
43. Merrick GS, Butler WM, Wallner KE, et al: Prostate-specific antigen spikes after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 54:450-456, 2002.
44. Cox JD, Grignon DJ, Kaplan RS, et al: Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997.
45. Hanlon AL, Hanks GE: Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. Int J Radiat Oncol Biol Phys 46:559-566, 2000.
46. Horwitz EM, Vicini FA, Ziaja EL, et al: The correlation between the ASTRO consensus panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. Int J Radiat Oncol Biol Phys 41:267-272, 1998.
47. Taylor JMG, Griffith KA, Sandler HM: Definitions of biochemical failure in prostate cancer following radiation therapy. Int J Radiat Oncol Biol Phys 50:1212-1219, 2001.
48. Horwitz E, Uzzo R, Hanlon A, et al: Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone. J Urol 169:2157-2159, 2003.
49. Shekarriz B, Upadhyay J, Wood DP: Intraoperative, perioperative, and long-term complications of radical prostatectomy. Urol Clin North Am 28:639-653, 2001.
50. Stone NN, Stock RG: Complications following permanent prostate brachytherapy. Eur Urol 41:427-433, 2002.
51. Inrocci L, Slob AK, Levendag PC: Sexual (dys)function after radiotherapy for prostate cancer: A review. Int J Radiat Oncol Biol Phys 52:681-693, 2002.
52. Stanford JL, Feng Z, Hamilton AS, et al: Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcomes Study. JAMA 283:354-360, 2000.
53. Kao T-C, Cruess DF, Garner D, et al: Multicenter patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy. J Urol 163:858, 2000.
54. Potosky AL, Legler J, Albertsen PC, et al: Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 92:1582-1592, 2000.
55. Catalona WJ, Carvalhal GF, Mager DE, et al: Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 162:433-438, 1999.
56. Potters L, Toore T, Fearn PA, et al: Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 50:1235-1242, 2001.
57. Merrick GS, Butler WM, Galbreath RW, et al: Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 52:893-902, 2002.
58. Zippe CD, Kedia AW, Kedia K, et al: Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology 52:963-966, 1998.
59. Begg C, Reidel E, Bach P, et al: Variations in morbidity after radical prostatectomy. N Eng J Med 346:1138-1144, 2002.
60. Talcott JA, Clark JA, Stark PC, et al: Long-term treatment related complications of brachytherapy for early prostate cancer: A survey of patients previously treated. J Urol 166:494-499, 2001.
61. Stone NN, Ratnow ER, Stock RG: Prior transurethral resection does not increase morbidity following real-time ultrasound-guided prostate seed implantation. Tech Urol 6:123-127, 2000.
62. Fichtner J, Gillitzer R, Melchior S, et al: Perineal complications following radical prostatectomy. Aktuelle Urologie 34:223-225, 2003
63. Dahm P, Silverstein AD, Weizer AZ, et al: A longitudinal assessment of bowel related symptoms and fecal incontinence following radical perineal prostatectomy. J Urol 169:2220-2224, 2003.
64. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 360:103-108, 2002.
65. Schellhammer PF: Interview with Dr. Schellhammer. Prostate Cancer Update 2:12-16, 2003.
66. Holmberg L, Bill-Axelson A, Helgesen F, et al: A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347:781-789, 2002.